or Try an Advanced Search...

    Technical Analysis for ASRT - Assertio Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 0.92 4.08% 0.04
    ASRT closed up 4.08 percent on Wednesday, May 1, 2024, on 74 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
    Earnings due: May 6
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Up
    Historical ASRT trend table...
    Date Alert Name Type % Chg
    Crossed Above 50 DMA Bullish 0.00%
    Up 3 Days in a Row Strength 0.00%
    Up 4 Days in a Row Strength 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 4.08%
    Crossed Above 20 DMA Bullish 4.08%
    Up 3 Days in a Row Strength 4.08%
    20 DMA Resistance Bearish 8.63%
    MACD Bullish Signal Line Cross Bullish 8.63%
    Inside Day Range Contraction 11.23%
    New 52 Week Low Weakness 17.34%
    Older End-of-Day Signals for ASRT ...

       Recent Intraday Alerts

    Alert Time
    Up 5% about 2 hours ago
    50 DMA Resistance about 4 hours ago
    60 Minute Opening Range Breakout about 5 hours ago
    Rose Above Previous Day's High about 5 hours ago
    Rose Above 50 DMA about 5 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ASRT Chart by TradingView
    Basic chart:

    Profile

    Assertio Therapeutics, Inc. Description

    Assertio Therapeutics, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), Cambia (diclofenac potassium for oral solution), Xartemis XR and Zipsor (diclofenac potassium). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia (PHN). Its Cambia (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.

    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Pharmaceutical Organ Systems Pain Organic Compounds Chemical Compounds Opioids Potassium Analgesics Acute Pain Neuropathic Pain Migraine Peripheral Neuropathy Amino Acids Diabetic Peripheral Neuropathy Treatment Of Migraine Postherpetic Neuralgia

    Is ASRT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 25 Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024
    Apr 3 Sig Kirk Joins Assertio Board of Directors
    Apr 1 Assertio to Present at LD Micro Invitational Conference in New York City
    Mar 14 These Analysts Think Assertio Holdings, Inc.'s (NASDAQ:ASRT) Earnings Are Under Threat
    Mar 12 Assertio Holdings Inc (ASRT) Reports Mixed Fourth Quarter and Full Year 2023 Financial Results
    Mar 12 Assertio Holdings files for $150M mixed shelf
    Mar 12 Assertio Holdings, Inc. (NASDAQ:ASRT) Q4 2023 Earnings Call Transcript
    Mar 12 Q4 2023 Assertio Holdings Inc Earnings Call
    Mar 11 Assertio Holdings Inc. (ASRT) Q4 2023 Earnings Call Transcript
    Mar 11 Assertio Holdings Non-GAAP EPS of $0.11, revenue of $32.99M misses by $0.82M
    See more ASRT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 8.01
    52 Week Low 0.7324
    Average Volume 1,030,152
    200-Day Moving Average 1.86
    50-Day Moving Average 0.91
    20-Day Moving Average 0.86
    10-Day Moving Average 0.84
    Average True Range 0.07
    RSI (14) 54.75
    ADX 19.92
    +DI 23.98
    -DI 21.84
    Chandelier Exit (Long, 3 ATRs) 0.75
    Chandelier Exit (Short, 3 ATRs) 0.94
    Upper Bollinger Bands 0.97
    Lower Bollinger Band 0.74
    Percent B (%b) 0.77
    BandWidth 26.53
    MACD Line -0.02
    MACD Signal Line -0.03
    MACD Histogram 0.0103
    Fundamentals Value
    Market Cap 87.21 Million
    Num Shares 94.7 Million
    EPS -2.74
    Price-to-Earnings (P/E) Ratio -0.34
    Price-to-Sales 0.45
    Price-to-Book 0.39
    PEG Ratio 1.20
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.03
    Resistance 3 (R3) 1.02 0.98 1.01
    Resistance 2 (R2) 0.98 0.95 0.98 1.00
    Resistance 1 (R1) 0.95 0.94 0.97 0.96 1.00
    Pivot Point 0.91 0.91 0.92 0.91 0.91
    Support 1 (S1) 0.88 0.88 0.90 0.89 0.85
    Support 2 (S2) 0.84 0.87 0.84 0.84
    Support 3 (S3) 0.81 0.84 0.83
    Support 4 (S4) 0.82